iSERA Lifesciences Ltd (534920)
Latest quarterly results (Q4 FY26)
In its latest reported quarter, Q4 FY26, iSERA Lifesciences' revenue was ₹1.2 Cr, and net profit ₹0.6 Cr (+139.1% year on year); the operating margin was 49.1%.
| Q4 FY26 (₹ Cr) | Value | YoY vs Q4 FY25 | QoQ |
|---|---|---|---|
| Revenue | ₹1.2 | — | +510.5% |
| Operating profit | ₹0.6 | from loss | from loss |
| Net profit | ₹0.6 | +139.1% | from loss |
| EPS (₹) | 0.65 | +140.7% | from loss |
| Operating margin | 49.1% | — | — |
📢 Recent Corporate Announcements
iSERA Lifesciences Limited has submitted continual disclosures under SEBI (PIT) Regulations reflecting equity share allotments executed on a share swap basis. Multiple promoters and allottees received equity shares, including Shubhangi Dhanraj Garad acquiring 27,55,000 shares (4.95%) and Sumeet Dhanraj Garad receiving 11,92,000 shares (4.06%). Other significant allotments include Dhairyasheel Vasantrao Yadav acquiring 4,50,500 shares valued at Rs 2.17 Cr, taking total holding to 15,65,500 shares (6.37%). The allotment date specified across filings was October 01, 2026.
- Shubhangi Dhanraj Garad acquired 27,55,000 equity shares (4.95% of paid-up capital) via share swap
- Sumeet Dhanraj Garad acquired 11,92,000 shares representing 4.06% of capital
- Dhairyasheel Vasantrao Yadav was allotted 4,50,500 shares worth Rs 2.17 Cr, increasing holding to 15,65,500 shares (6.37%)
- Babasaheb Mahadeo Bhosale acquired 80,000 shares valued at Rs 38.56 lakh
- Allotment of shares took place on October 01, 2026 pursuant to preferential allotment
Promoter Archana Kakasaheb Lonkar was allotted 4,95,000 equity shares in iSERA Lifesciences via preferential allotment (share swap) on October 1, 2026. Following this issuance, her absolute holding increased from 7,00,000 shares to 11,95,000 shares. However, due to a massive expansion in total share capital from 84,08,972 shares (Rs 8.41 Cr) to 2,45,91,772 shares (Rs 24.59 Cr), her percentage holding diluted from 8.32% to 4.86%.
- Promoter allotted 4,95,000 equity shares via preferential allotment under a share swap
- Absolute holding increased from 7,00,000 shares to 11,95,000 shares
- Percentage stake decreased from 8.32% to 4.86% due to total equity base expansion
- Total share capital expanded nearly threefold from 84,08,972 shares to 2,45,91,772 shares (Rs 24.59 Cr)
iSERA Lifesciences Limited has approved the allotment of 1,61,82,800 equity shares of face value Rs 10 each at an issue price of Rs 48.20 per share (including Rs 38.20 share premium). The total transaction value stands at approximately Rs 78 Cr, which dwarfs the company's TTM revenue of Rs 16 Cr and net worth of Rs 8 Cr. The allotment is executed via a 1:1 share swap with shareholders of iSERA Biological Limited. The issue covers 196 allottees spanning promoters, promoter groups, and marquee non-promoter individuals.
- Allotment of 1,61,82,800 fully paid-up equity shares approved on October 01, 2026
- Issued at Rs 48.20 per share (Rs 10 face value plus Rs 38.20 premium)
- Executed via a 1:1 share swap ratio for equity shares of iSERA Biological Limited
- Transaction covers 196 allottees including promoter and non-promoter categories
iSERA Lifesciences Limited has approved the allotment of 1,61,82,800 equity shares of face value Rs 10 each at an issue price of Rs 48.20 per share (including Rs 38.20 share premium). The total transaction value stands at approximately Rs 78 Cr, which dwarfs the company's TTM revenue of Rs 16 Cr and net worth of Rs 8 Cr. The allotment is executed via a 1:1 share swap with shareholders of iSERA Biological Limited. The issue covers 196 allottees spanning promoters, promoter groups, and marquee non-promoter individuals.
- Allotment of 1,61,82,800 fully paid-up equity shares approved on October 01, 2026
- Issued at Rs 48.20 per share (Rs 10 face value plus Rs 38.20 premium)
- Executed via a 1:1 share swap ratio for equity shares of iSERA Biological Limited
- Transaction covers 196 allottees including promoter and non-promoter categories
iSERA Lifesciences reported zero revenue from operations for the quarter ended June 30, 2026, a sharp decline from Rs 1.16 crore in the preceding quarter. The company posted a net loss of Rs 33.62 lakh, compared to a profit of Rs 54.98 lakh in Q4 FY26 and a loss of Rs 1.54 lakh in the same quarter last year. Total expenses for the quarter were Rs 33.62 lakh, almost entirely driven by 'Other Expenses' of Rs 31.31 lakh. The company's reserves remain negative at Rs -49.81 lakh, highlighting continued financial instability.
- Revenue from operations dropped to Rs 0 in Q1 FY27 from Rs 1.16 crore in the previous quarter.
- Net loss widened significantly to Rs 33.62 lakh from a loss of Rs 1.54 lakh in Q1 FY26.
- Other expenses accounted for 93% of total quarterly expenditure at Rs 31.31 lakh.
- Negative reserves increased to Rs -49.81 lakh as of June 30, 2026.
- Paid-up equity share capital remains constant at Rs 840.90 lakh.
iSERA Lifesciences (formerly Covidh Technologies) reported a sharp decline in performance for Q1 FY27, with operating revenue dropping to zero from ₹1.16 Cr in the previous quarter. The company posted a net loss of ₹33.62 Lakhs, compared to a profit of ₹54.88 Lakhs in Q4 FY26. Total expenses for the quarter were ₹39.39 Lakhs, largely driven by 'Other Expenses' of ₹37.08 Lakhs. The company continues to struggle with negative reserves, which widened to ₹43.81 Lakhs.
- Revenue from operations fell to ₹0.00 for the quarter ended June 30, 2026, compared to ₹1.16 Cr in the preceding quarter.
- Net loss stood at ₹33.62 Lakhs for Q1 FY27, a reversal from the ₹54.88 Lakhs profit recorded in Q4 FY26.
- Other Expenses accounted for ₹37.08 Lakhs, representing over 94% of the total quarterly expenditure.
- Negative reserves (excluding revaluation) increased to ₹43.81 Lakhs from ₹16.19 Lakhs in the previous quarter.
- Basic and Diluted EPS for the quarter was negative ₹1.60.
iSERA Lifesciences Ltd has scheduled a board meeting for August 7, 2026, to consider and approve its unaudited financial results for the quarter ended June 30, 2026. The company currently operates with a TTM revenue of Rs 16 Cr and a net worth of Rs 0 Cr, resulting in a high debt-to-equity ratio of 22.17. Despite these fundamentals, the stock has seen an extreme 12-month price return of 4497.4%. The trading window for designated persons has been closed since July 1, 2026, in compliance with insider trading regulations.
- Board meeting scheduled for August 7, 2026, to approve Q1 FY27 results
- Trading window closure effective from July 1, 2026, until 48 hours post-results
- Company reports a TTM revenue of Rs 16 Cr against a debt of Rs 11 Cr
- Promoter holding recently stabilized at 58.63% in March 2026 after significant fluctuations
- Stock has delivered a 4497.4% return over the last 12 months
Financial Performance
Financial analysis data not yet available for this company.
Operational Drivers
Operational analysis data not yet available for this company.
Strategic Growth
Strategic growth analysis not yet available for this company.
External Factors
External factors analysis not yet available for this company.
Regulatory & Governance
Regulatory analysis not yet available for this company.
Risk Analysis
Risk analysis not yet available for this company.
